StemSynergy Therapeutics, Inc.
"Innovative Stem Cell Research. Targeted Cancer Therapeutics."

Scientific Advisory Board

J. Michael Bishop, MD

Professor and Director, The G.W. Hooper Foundation at UCSF.

Chancellor Emeritus of UCSF.

Dr. Bishop directs the G. W. Hooper Research Foundation, which conducts multidisciplinary research on human disease. He maintains an active research lab with a focus on the molecular basis of cancer. Dr. Bishop has been won awards for his excellence in Teaching. Dr. Bishop was Chancellor UCSF. His honors and awards include the Albert Lasker Basic Medical Research Award, the Armand Hammer Cancer Prize, Award for Distinguished Research in the Biomedical Sciences from the American Association of Medical Colleges, and the 2003 National Medal of Science. He was appointed chair of the National Cancer Advisory Board by President Bill Clinton. Dr. Bishop is a member of several professional and honorary societies, including the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences.

Dr. Bishop shared the 1989 Nobel Prize in physiology or medicine with Harold Varmus.

Melanie Cobb, PhD

Jane and Bill Browning, Jr. Chair in Medical Science, UT Southwestern Medical Center.

Habarecht Dean of the Southwestern Graduate School of Biomedical Sciences.

Dr. Melanie Cobb received her PhD in biological chemistry from Washington University in St. Louis in the laboratory of Dr. Garland Marshall, followed by postdoctoral work with Dr. Ora Rosen at the Albert Einstein College of Medicine in New York. She is currently a Professor in the Department of Pharmacology at UT Southwestern. She has served on the advisory boards of numerous companies including Pfizer, Celgene, Schering Plough, Roche and Promega. She is internationally recognized for her work on cellular regulatory mechanisms, for which she was recently elected to the prestigious National Academy of Sciences.

Frank McCormick, PhD, FRS

Associate Dean, UCSF School of Medicine.

David A. Wood Distinguished Professor of Tumor Biology and Cancer Research, UCSF.

Director, UCSF Comprehensive Cancer Center and Cancer Research Institute.

Dr. McCormick is director of the University of California, San Francisco (UCSF) Comprehensive Cancer Center and Cancer Research Institute, one of the largest multidisciplinary research and clinical care organizations in the western United States. Prior to joining UCSF, Dr. McCormick held prominent positions with several Bay Area firms pursuing cancer-related therapies, including Cetus Corporation (1981 – 1991) and Chiron Corporation (1991 – 1992). In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Currently, Dr. McCormick serves on the SAB of BiPar Sciences, Fluidigm, Exelexis, Onyx, and numerous scientific foundations. His research focuses on fundamental differences between normal and cancer cells that enable the development of novel therapeutic strategies.

Jake Reder, PhD

Cofounder, Director, & Chief Executive Officer, Celdara Medical, LLC.

Jake founded the New Ventures Office at Dartmouth Medical School in 2008 and serves as its first Director. Previously Jake led new business platforms and projects, external innovation, and knowledge management initiatives at Cabot Corporation. He started up Cabot’s Printed Electronics Business and Optical Composites Platform, and was a member of Cabot’s Research Council, Technology Board, and Nanotechnology EHS Council. Jake joined Cabot’s New Business Development team from PolyTechnos Venture-Partners, a Munich-based venture capital firm where he advised on early stage technology investments. Jake has studied, worked, and taught in Canada, Germany, and the United States. He has served on the Boards of Virtici Corporation, the Center for Biological and Environmental Nanotechnology at Rice University, TechConnect, Everybody Wins! Metro Boston, the Cabot Boston Credit Union, and the Billerica Partners for Education. Jake earned a BSc with First Class Honours from the University of Waterloo, and a PhD (Chemistry) as a Brown-Wetherill Fellow at Purdue University and Ludwig Maximilians Universität.

Kevan Shokat, PhD

Investigator, Howard Hughes Medical Institute.

Professor and Vice-Chair of Cellular and Molecular Pharmacology, UCSF.

Professor of Chemistry, UC Berkeley.

Dr. Shokat received his PhD in Chemistry from the University of California, Berkeley, and began his independent research career at Princeton University, where he developed novel chemical methods for probing protein kinase signaling cascades using unnatural ATP analogs and uniquely specific protein kinase inhibitors. Dr. Shokat moved to the Bay Area in 1999, and in 2001 he was named Full Professor at UCSF and UC Berkeley. Dr. Shokat is cofounder of Cellular Genomics Inc and of Intellikine, Inc and is an advisor to BioSeek, Genentech, and 5AM Ventures. His research focuses on identifying small molecule inhibitors of lipid and protein kinases.

Scientific Team

SSTI has a multidisciplinary team of scientists.

Meet the Team


Meet the Leadership behind StemSynergy Therapeutics, Inc.

Meet Leadership

Cancer Research

Targeting the developmental pathways that drive cancer.

Cancer Research